Abstract
This Practice Point commentary examines a recent systematic review by Bennett et al. that summarized 51 controlled trials of the erythropoiesis-stimulating agents (ESAs) darbepoetin and epoetin in patients with cancer. The review focused exclusively on the safety of this class of drugs. Key findings included an increased risk of venous thromboembolism (previously reported) and poorer overall survival (a new finding) in patients who received ESAs, compared with controls. This commentary discusses the evolving safety concerns regarding ESAs, and highlights the uncertainties about which groups of patients are at risk and whether some administration strategies are safer than others. The regulatory and reimbursement environments for these compounds are in flux, and until additional data are available, a conservative treatment approach is appropriate.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bennett CL et al. (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914–924
Rizzo JD et al. (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26: 132–149
Bohlius J et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Systematic Reviews 2006 Issue 2 Art No.: CD003407. DOI: 10.1002/14651858.CD003407.pub4
Wilson J et al. (2007) A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 11: 1–202, iii–iv
FDA (online 13 March 2008) FDA briefing document. Oncologic Drugs Advisory Board. [http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-01-FDA.pdf] (accessed 24 April 2008)
Phurrough S et al. (2007) Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). [https://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2= viewdecisionmemo.asp&id=203&] (accessed 24 April 2008)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dronca, R., Steensma, D. VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia. Nat Rev Clin Oncol 5, 504–505 (2008). https://doi.org/10.1038/ncponc1202
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1202
This article is cited by
-
Bloodless cancer treatment results of patients who do not want blood transfusion: single center experience of 77 cases
Supportive Care in Cancer (2010)